Evidence map›Paper›PMID 27341104›Full record

ArticlePLoS neglected tropical diseases2016

A Knowledge, Attitudes and Practices Survey Conducted Three Years after Halting Ivermectin Mass Treatment for Onchocerciasis in Guatemala.

Frank O Richards, Robert E Klein, Oscar de León, Renata Mendizábal-Cabrera, Alba Lucía Morales, Vitaliano Cama, Carol G Crovella, Carlos E Díaz Espinoza, Zoraida Morales, Mauricio Sauerbrey and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Frank O RichardsRiver Blindness Elimination Program, Lymphatic Filariasis Elimination Program, and Schistosomiasis Control Program, The Carter Center, Atlanta, Georgia, United States of America.
Robert E KleinCenter for Health Studies (CHS), Universidad del Valle de Guatemala (UVG), Guatemala City, Guatemala.
Oscar de LeónCenter for Health Studies (CHS), Universidad del Valle de Guatemala (UVG), Guatemala City, Guatemala.
Renata Mendizábal-CabreraCenter for Health Studies (CHS), Universidad del Valle de Guatemala (UVG), Guatemala City, Guatemala.
Alba Lucía MoralesOnchocerciasis Elimination Program for the Americas, The Carter Center, Guatemala City, Guatemala.
Vitaliano CamaDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Carol G CrovellaOnchocerciasis Sub-Program, National Ministry of Health, Guatemala City, Guatemala.
Carlos E Díaz EspinozaOnchocerciasis Sub-Program, National Ministry of Health, Guatemala City, Guatemala.
Zoraida MoralesOnchocerciasis Sub-Program, National Ministry of Health, Guatemala City, Guatemala.
Mauricio SauerbreyOnchocerciasis Elimination Program for the Americas, The Carter Center, Guatemala City, Guatemala.
Nidia RizzoCenter for Health Studies (CHS), Universidad del Valle de Guatemala (UVG), Guatemala City, Guatemala.
Universidad del Valle de Guatemala · GTMinistry of Public Health and Social Assistance · GTCarter Center · USCenters for Disease Control and Prevention · US

Funding

CGH CDC HHS U51 GH000970
6 · The paper itself

Abstract

backgroundMass drug administration (MDA) with ivermectin for onchocerciasis was provided in Guatemala's Central Endemic Zone (CEZ) over a 24 year period (1988-2011). Elimination of Onchocerca volvulus transmission was declared in 2015 after a three year post MDA surveillance period (2012-2014) showed no evidence of recrudescence. The purpose of the present study was to evaluate the knowledge, attitudes and practices (KAP) towards onchocerciasis and ivermectin among residents in the post endemic CEZ. A major interest in this study was to determine what community residents thought about the end of the ivermectin MDA program. METHODOLOGY/PRINCIPAL

findingsA total of 148 interviews were conducted in November 2014 in four formerly hyperendemic communities using a standard questionnaire on smart phones. The majority (69%) of respondents knew that the MDA program had ended because the disease was no longer present in their communities, but a slight majority (53%) was personally unsure that onchocerciasis had really been eliminated. Sixty-three percent wanted to continue to receive ivermectin because of this uncertainty, or because ivermectin is effective against intestinal worms. Eighty-nine percent of respondents said that they would seek medical attention immediately if a family member had symptoms of onchocerciasis (especially the presence of a nodule), which is a finding very important for ongoing surveillance. CONCLUSIONS/SIGNIFICANCE: Many respondents wanted to continue receive ivermectin and more than half did not believe onchocerciasis had been eliminated. The ministry of health outreach services should be prepared to address ongoing concerns about onchocerciasis in the post endemic CEZ.

Indexed as

Health Knowledge, Attitudes, PracticeAdultAntiparasitic AgentsFemaleGuatemalaHealth EducationHealth SurveysHumansIvermectinMaleOnchocerciasisSurveys and QuestionnairesAntiparasitic AgentsIvermectin

Identifiers

PMID27341104
PMCPMC4920414
OpenAlexW2460323643

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.